Get the Weekly Intelligence Brief — top committee picks every Sunday.

CVSA vs INGR

Covista Inc. vs Ingredion — AI-powered side-by-side comparison
CVSA
Covista Inc.
57
Watch
VS
INGR
Ingredion
62
Buy
MetricCVSAINGR
AI Score 57 62
Price $125.97 $104.70
P/E Ratio 16.60× 11.25×
ROE 17.4% 16.8%
Revenue Growth YoY
Gross Margin 57.3% 23.7%
Debt / Equity 0.63× 0.39×
Dividend Yield 0.0% 3.1%
RSI (14) 48.4 57.8
Beta 0.623 0.606
Expected Upside +1.6%

AI Committee View

Current Innellis committee reasoning for CVSA versus INGR.
INGR leads by 5 points.

INGR scores 62/100 (Buy) versus CVSA at 57/100 (Watch).

CVSA Committee View
50% agreement
6 analysts

The committee is genuinely divided. Macro Analyst sees a compelling case — vix regime is low -- calm backdrop supports risk-taking. Risk Analyst remains cautious — current ratio of 0.82 is tight -- limited short-term liquidity cushion. This disagreement is itself the signal — the setup is not clean in either direction.

Bull Case
  • ROE of 16.6% shows genuine earnings power backing the valuation — Value
  • Price structure making higher highs and higher lows — Technical
  • MACD histogram positive -- bullish momentum — Technical
Bear Case
  • Daily trend (uptrend) conflicts with the weekly trend (downtrend) -- fighting the larger trend — Technical
  • Current ratio of 0.82 is tight -- limited short-term liquidity cushion — Risk
  • Bollinger bandwidth of 24.6% signals elevated volatility — Risk
INGR Committee View
60% agreement
5 analysts

The primary driver is vix regime is low -- calm backdrop supports risk-taking. The main limiting factor is revenue declining -1.4% yoy -- this is not a growth story right now. The committee is constructive but not yet at full conviction.

Bull Case
  • P/E of 11.1 is inexpensive for the broad market — Value
  • Dividend yield of 3.2% pays you to wait — Value
  • Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
Bear Case
  • Revenue declining -1.4% YoY -- this is not a growth story right now — Growth
  • EPS declining -10.3% YoY despite any revenue growth — Growth
Want the full breakdown?
Committee votes, technicals, and trade plans for both companies.
CVSA Full Analysis INGR Full Analysis